Currently, Legend Biotech Corp ADR [LEGN] is trading at $48.73, down -1.10%. An important factor to consider is whether the stock is rising or falling in short-term value. The LEGN shares have gain 6.12% over the last week, with a monthly amount drifted -14.07%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Legend Biotech Corp ADR [NASDAQ: LEGN] stock has seen the most recent analyst activity on June 17, 2024, when Truist initiated its Buy rating and assigned the stock a price target of $88. Previously, H.C. Wainwright reaffirmed its Buy rating on May 24, 2024, and dropped its price target to $73. On May 23, 2024, Deutsche Bank initiated with a Buy rating and assigned a price target of $60 on the stock. Scotiabank upgraded its rating to a Sector Outperform but stick to its price target of $65 on April 17, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $82 as its price target on April 03, 2024. Raymond James started tracking with a Outperform rating for this stock on March 13, 2024, and assigned it a price target of $86. In a note dated December 19, 2023, Scotiabank initiated an Sector Perform rating.
This stock has fluctuated between a low of $38.60 and a high of $70.78 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $78.78 within the next 12 months. Legend Biotech Corp ADR [NASDAQ: LEGN] shares were valued at $48.73 at the most recent close of the market. An investor can expect a potential return of 61.67% based on the average LEGN price forecast.
Analyzing the LEGN fundamentals
Trailing Twelve Months sales for Legend Biotech Corp ADR [NASDAQ:LEGN] were 455.99M which represents 154.36% growth. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at -0.76%, Pretax Profit Margin comes in at -0.63%, and Net Profit Margin reading is -0.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.23 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.38 points at the first support level, and at 46.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 50.76, and for the 2nd resistance point, it is at 52.78.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Legend Biotech Corp ADR [NASDAQ:LEGN] is 4.84. On the other hand, the Quick Ratio is 4.78, and the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 19.57, the price to book ratio is 7.70.
Transactions by insiders
Recent insider trading involved Huang Ying, Officer, that happened on Sep 25 ’24 when 1504.0 shares were purchased. Officer, Macomber Lori completed a deal on Sep 20 ’24 to buy 90060.0 shares. Meanwhile, Director Yau Wai Man Philip bought 1946.0 shares on Sep 20 ’24.
